This important step in ContextVision’s deep learning strategy generates the opportunity for a leading role within digital pathology, a market estimated to be worth $157 million USD by 2018.
STOCKHOLM – June 29, 2016 – ContextVision, the leading provider of medical image processing software, has filed a patent for a new method using high-precision deep learning within digital pathology. The ongoing digitalization of this market allows for automated image analysis, and this method will allow ContextVision to develop new, unique decision support tools based on true data instead of subjective evaluations.
“The method we have invented enables the development of new products with much higher accuracy and precision, and hence Contextvision will have a unique competitive edge” says Anita Tollstadius, CEO.
Currently, histopathology samples are stained with HE (hematoxylin-eosin) in clinical routine, creating images that are challenging to interpret and; therefore, subjective in evaluation by different pathologists, resulting in significant variation. The inter-observer variability in Gleason grading of prostate biopsies is especially prominent, with disagreement seen in up to 46 percent of the cases. There is a great need for improved diagnostic methods, as inadequate diagnosis results in poor treatment.
The patent application covers a method that uses super-specific staining with immunofluorescence. This enables training of the deep learning algorithms to use objective true data instead of subjective evaluations, but the developed analysis will be applied to routine HE stained samples.
“The new invention has broad implications for ContextVision as the method can be used for many different cancer types, even if we initially focus on prostate cancer” says Tollstadius.
For further information, please contact ContextVision’s CEO, Anita Tollstadius, telephone +46 70 337 30 26
ContextVision is a medical technology company specializing in image analysis and image processing. Its cutting-edge technology helps doctors more accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision has decided to take a lead position within deep learning, the latest technology within artificial intelligence. ContextVision is currently investing heavily in this field to develop a broader product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography and is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit www.contextvision.com.